Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 4, 2006, Pages 417-421

  Kiladjian, Jean Jacques ^a   Rain, Jean Didier ^b   Bernard, Jean Francois ^a   Briere, Jean ^a   Chomienne, Christine ^b   Fenaux, Pierre ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Anagrelide; Essential thrombocythemia; Hydroxyurea; Interferon; Leukemogenic risk; Pipobroman; Polycythemia vera

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; IMATINIB; JANUS KINASE 2; PHOSPHORUS; PHOSPHORUS 32; PIPOBROMAN; RIBONUCLEOTIDE REDUCTASE;

ACUTE LEUKEMIA; AGE; ARTICLE; CHROMOSOME 17P; CLINICAL TRIAL; CYTOGENETICS; DEATH; DISEASE COURSE; DRUG CHOICE; FOLLOW UP; FRANCE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEUKEMOGENESIS; LIFE EXPECTANCY; META ANALYSIS; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; SOLID TUMOR; SYSTEMATIC REVIEW; THROMBOCYTHEMIA; THROMBOSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; JANUS KINASE 2; LEUKEMIA; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; PIPOBROMAN; POLYCYTHEMIA VERA; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, HEMORRHAGIC; TIME FACTORS;

EID: 33745714754     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-942762     Document Type: Article

References (42)

1. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004;15:67-84
2. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-232
3. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005;130:174-195
4. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-143
5. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17-23
6. Murphy S, Peterson P, Hand H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997;34: 29-39
7. Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 1999;78:389-392
8. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev 2001;15:121-131
9. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequel of therapy, or a combination of both? Semin Hematol 2004;41:15-17
10. Berk PD, Wassermann LR, Fruchtman SM, Goldberg JT. Treatment of polycythaemia vera, a summary of clinical trends conducted by the polycythaemia vera sub-group. In: Wasserman LP, Berk PD, eds. Polycythaemia Vera and the Myeloproliferative Disorders. Philadelphia: WB Saunders; 1995:166-194
11. European Organisation for Research on Treatment of Cancer. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomised trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organisation for Research on Treatment of Cancer (EORTC). Br J Cancer 1981;44:75-80
12. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
13. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148
14. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397
15. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
16. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-1953
17. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation and constitutive mobilization of CD34-positive cells into peripheral blood in myeloproliferative disorders. Blood 2006;107: 3676-3682
18. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2005;107:3339-3341
19. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136
20. Monto RW, Tenpas A, Battle JF, Rohn RJ, Louis J, Louis NB. A-8103 in polycythemia. JAMA 1964;190:833-836
21. Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J Clin Oncol 1984;2:558-561
22. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000;85:1011-1018
23. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370-3377
24. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124
25. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670
26. Modan B, Lilienfeld AH. Polycythemia vera and leukemia. The role of radiation treatment. A study of 1222 patients. Medicine (Baltimore) 1965;44:305-344
27. Tubiana M, Flamant R, Attie E, Hayat M. A study of hematological complications occurring in patients with polycythemia vera treated with 32P (based on a series of 296 patients). Blood 1968;32:536-548
28. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand 1962;44:155-157
29. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 2003;4:198-207
30. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622
31. Merlat A, Lai JL, Sterkers Y, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 1999;13:250-257
32. Chomienne C, Rain JD, Briere J. French PV and ET Study Groups. Risk of leukemic transformation in PV and ET patients. Pathol Biol (Paris) 2004;52:289-293
33. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-2663
34. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761
35. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-447
36. Spivak J. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-4290
37. Andersson PO, Ridell B, Wadenvik H, Kutti J. Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment. Ann Hematol 2000;79:40-42
38. Hsiao HH, Ito Y, Sashida G, Ohyashiki JH, Ohyashiki K. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Leuk Res 2005;29:1247-1252
39. Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand 1962;172:513-523
40. Petti MC, Spadea A, Awisati G, et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia 1998;12:869-874
41. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004;41:15-17
42. Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Br J Haematol 2003;120:177-186